发明公开
EP3185870A1 BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR
审中-公开
利用BTK抑制剂预测DLBCL对治疗反应的生物标志物
- 专利标题： BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR
- 专利标题（中）： 利用BTK抑制剂预测DLBCL对治疗反应的生物标志物
-
申请号： EP15828160.0申请日： 2015-07-31
-
公开(公告)号： EP3185870A1公开(公告)日： 2017-07-05
- 发明人: SCHWEIGHOFER, Karl , ECKERT, Karl , KUO, Hsu-Ping , CHANG, Betty , BEAUPRE, Darrin , CHEUNG, Leo
- 申请人： Pharmacyclics LLC
- 申请人地址： 995 East Arques Avenue Sunnyvale, CA 94085 US
- 专利权人： Pharmacyclics LLC
- 当前专利权人： Pharmacyclics LLC
- 当前专利权人地址： 995 East Arques Avenue Sunnyvale, CA 94085 US
- 代理机构： HGF Limited
- 优先权： US201462032430P 20140801; US201562119668P 20150223; US201562127484P 20150303
- 国际公布： WO2016019341 20160204
- 主分类号： A61K31/519
- IPC分类号： A61K31/519
摘要：
Disclosed herein, are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes (e.g. EP300, MLL2, BCL-2, RB1, LRP1B, PIM1, TSC2, TNFRSF11A, SMAD4, PAX5, CARD11, ACTG2, LOR, GAPT, CCND2, SELL, GEN1, HDAC9, CD79B, MYD88, and ROS1) or biomarker gene expression levels for stratifying a patient having a hematological malignancy such as DLBCL for treatment, and administering a TEC inhibitor to selected patients. Also disclosed herein are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes, or biomarker gene expression levels for monitoring a patient during treatment of a hematological malignancy such as DLBCL or FL or for optimizing a treatment regimen with a TEC inhibitor.
信息查询
IPC分类:
